JAZZ

#3333
Jazz Pharmaceuticals plc - Ordinary Shares
2.3 6 USD
+0.47%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
2.36
2.36
1年のレンジ
2.36
243.32
1日の変化
+0.47%
月次変化
-98.83%
6か月変化
-98.64%
1年の変化
-98.31%
以前の終値
2.3 5
Open
2.3 6
安値
2.3 6
High
2.3 6
ボリューム
137
チャート全体を表示 Full chart

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 148.38 M
  • Employee 2 890
  • Founded 2003
  • CEO Bruce C Cozadd
  • Website www.jazzpharmaceuticals.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry 生物工学
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-29.11
売上高対価格比率
2.43

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America.

ニュース